Investors have yet to fully bake in risks of Anacor's two lead drugs flopping commercially.
Conatus Pharmaceuticals is an early-stage developer of drugs to treat diseases of the liver with a favorable risk-reward profile, particularly after recent investor selling in the biotech sector has created some nice values.
The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.
Expect the Endocyte bear thesis to shift now that vintafolide has conditional approval in Europe and the lung cancer phase II study was positive.
Rigosertib performed pretty much as expected but the control arm of the study lived longer than anticipated, thereby causing the negative result.
Cempra's solithromycin may have an important safety advantage over competing compounds.
A look at the myriad ways cancer immunotherapy combinations might one day benefit patients.
Sangamo benefits from a Biogen partnership, but what does it mean for rivals Bluebird and Acceleron?
Innate Pharmaceuticals is developing a promising "checkpoint inhibitor" cancer drug and is partnered with Bristol-Myers Squibb.
Infinity's B-cell malignancy drug is seen as too far behind competitors but can combination therapy make it more relevant?